[go: up one dir, main page]

WO2001096398A3 - Proteines bruleuses de graisses excedentaires utilisees comme cibles dans le traitement de l'insuffisance cardiaque - Google Patents

Proteines bruleuses de graisses excedentaires utilisees comme cibles dans le traitement de l'insuffisance cardiaque Download PDF

Info

Publication number
WO2001096398A3
WO2001096398A3 PCT/US2001/019230 US0119230W WO0196398A3 WO 2001096398 A3 WO2001096398 A3 WO 2001096398A3 US 0119230 W US0119230 W US 0119230W WO 0196398 A3 WO0196398 A3 WO 0196398A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
treatment
targets
uncoupling proteins
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/019230
Other languages
English (en)
Other versions
WO2001096398A2 (fr
Inventor
Charles J Homcy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
COR Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by COR Therapeutics Inc filed Critical COR Therapeutics Inc
Priority to AU2001268461A priority Critical patent/AU2001268461A1/en
Publication of WO2001096398A2 publication Critical patent/WO2001096398A2/fr
Publication of WO2001096398A3 publication Critical patent/WO2001096398A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention porte sur des procédés d'identification d'un agent efficace dans le traitement de l'insuffisance cardiaque et de modulation de l'expression ou de l'activité de la protéine brûleuse de graisses excédentaires. Cette invention porte également sur des compositions et des procédés de traitement de l'insuffisance cardiaque.
PCT/US2001/019230 2000-06-15 2001-06-15 Proteines bruleuses de graisses excedentaires utilisees comme cibles dans le traitement de l'insuffisance cardiaque Ceased WO2001096398A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001268461A AU2001268461A1 (en) 2000-06-15 2001-06-15 Uncoupling proteins as targets for the treatment of heart failure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21153600P 2000-06-15 2000-06-15
US60/211,536 2000-06-15

Publications (2)

Publication Number Publication Date
WO2001096398A2 WO2001096398A2 (fr) 2001-12-20
WO2001096398A3 true WO2001096398A3 (fr) 2002-05-16

Family

ID=22787332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/019230 Ceased WO2001096398A2 (fr) 2000-06-15 2001-06-15 Proteines bruleuses de graisses excedentaires utilisees comme cibles dans le traitement de l'insuffisance cardiaque

Country Status (2)

Country Link
AU (1) AU2001268461A1 (fr)
WO (1) WO2001096398A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221413B2 (en) 2009-12-23 2019-03-05 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506630A1 (fr) * 2002-11-27 2004-06-17 Artesian Therapeutics, Inc. Detection des genes lies a l'insuffisance cardiaque et dosage therapeutique
WO2014209905A2 (fr) * 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Méthodes et compositions destinées à détecter et à diagnostiquer des maladies et des affections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045313A1 (fr) * 1997-04-04 1998-10-15 Amylin Pharmaceuticals, Inc. Proteine decouplante et procedes d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998045313A1 (fr) * 1997-04-04 1998-10-15 Amylin Pharmaceuticals, Inc. Proteine decouplante et procedes d'utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GENG Y-J ET AL: "APOPTOSIS OF CARDIAC MYOCYTES IN GSALPHA TRANSGENIC MICE", CIRCULATION RESEARCH, GRUNE AND STRATTON, BALTIMORE, US, vol. 84, no. 1, 8 January 1999 (1999-01-08), pages 34 - 42, XP001007327, ISSN: 0009-7330 *
KELLY LINDA J ET AL: "Peroxisome proliferator-activated receptors gamma and alpha mediated in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.", ENDOCRINOLOGY, vol. 139, no. 12, December 1998 (1998-12-01), pages 4920 - 4927, XP002182349, ISSN: 0013-7227 *
SILVA J ENRIQUE ET AL: "Regulation of the uncoupling protein gene expression.", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 136, no. 3, 1997, pages 251 - 264, XP000918584, ISSN: 0804-4643 *
VAN DER LEE KARIN A J M ET AL: "Effects of fatty acids on uncoupling protein-2 expression in the rat heart.", FASEB JOURNAL, vol. 14, no. 3, March 2000 (2000-03-01), pages 495 - 502, XP002182350, ISSN: 0892-6638 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10221413B2 (en) 2009-12-23 2019-03-05 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2

Also Published As

Publication number Publication date
AU2001268461A1 (en) 2001-12-24
WO2001096398A2 (fr) 2001-12-20

Similar Documents

Publication Publication Date Title
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
WO2003073999A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
IL189629A0 (en) Compositions containing human ctla-4 antibodies
IL183953A0 (en) Method of reducing oxidant induced damage of a food product, a pharmaceutical, or stored blood
WO2003074550A3 (fr) Composes de modulation de pin1 et procedes d'utilisation correspondant
ATE238307T1 (de) Substituierte porphyrinen
WO2001044247A3 (fr) Agents et methodes de traitement des maladies hyperplasiques
SI1427409T1 (sl) Postopki za zdravljenje ali preprečevanje vaskularnega vnetja z uporabo zaviralca(-ev) absorpcije sterola
WO2001017543A3 (fr) Compositions et procedes permettant la prevention ou le traitement du cancer et de la perte osseuse associee au cancer
ZA971183B (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants.
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
WO2002091858A8 (fr) Compositions anxiolytiques de marcgraviaceae contenant de l'acide betulinique ou des derives d'acide betulinique et procedes associes
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2003010291A3 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b
ZA200003768B (en) Methods and compositions for treating diseases and conditions of the eye.
EP0861663A3 (fr) Agent inhibiteur des ostéoclastes comprenant l'interleukin-18
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
WO2000071716A3 (fr) Dimeres, facteurs de croissance de l'endothelium vasculaire
WO2001096398A3 (fr) Proteines bruleuses de graisses excedentaires utilisees comme cibles dans le traitement de l'insuffisance cardiaque
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
WO2002062205A3 (fr) Methodes de diagnostic et de traitement des cardiopathies
WO2003087840A3 (fr) Proteine intervenant dans le cancer
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP